Cellectar Biosciences Inc (CLRB)

$2.03

-0.01

(-0.49%)

Market is closed - opens 7 PM, 04 Nov 2024

Performance

  • $2.02
    $2.07
    $2.03
    downward going graph

    0.49%

    Downside

    Day's Volatility :2.42%

    Upside

    1.93%

    downward going graph
  • $1.82
    $4.45
    $2.03
    downward going graph

    10.34%

    Downside

    52 Weeks Volatility :59.1%

    Upside

    54.38%

    downward going graph

Returns

PeriodCellectar Biosciences IncIndex (Russel 2000)
3 Months
2.53%
0.0%
6 Months
-40.64%
0.0%
1 Year
-23.4%
0.0%
3 Years
-78.85%
-26.4%

Highlights

Market Capitalization
82.3M
Book Value
$0.13
Earnings Per Share (EPS)
-2.43
PEG Ratio
0.0
Wall Street Target Price
12.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-166.0%
Return On Equity TTM
-724.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-47.4M
Diluted Eps TTM
-2.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.91
EPS Estimate Next Year
-2.83
EPS Estimate Current Quarter
-1.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Cellectar Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 520.69%

Current $2.03
Target $12.60

Technicals Summary

Sell

Neutral

Buy

Cellectar Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cellectar Biosciences Inc
Cellectar Biosciences Inc
-6.02%
-40.64%
-23.4%
-78.85%
-85.7%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-16.85%
-11.85%
3.27%
29.37%
171.22%
Biontech Se
Biontech Se
-6.94%
20.23%
16.39%
-62.26%
487.66%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
1.63%
79.81%
63.67%
58.45%
198.57%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.87%
17.46%
25.23%
149.18%
136.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cellectar Biosciences Inc
Cellectar Biosciences Inc
NA
NA
0.0
-3.91
-7.25
-1.66
NA
0.13
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.75
20.75
1.18
44.77
0.17
0.08
NA
242.47
Biontech Se
Biontech Se
160.8
NA
0.04
-2.76
-0.03
-0.02
NA
80.22
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.39
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.16
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cellectar Biosciences Inc
Cellectar Biosciences Inc
Buy
$82.3M
-85.7%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$101.7B
171.22%
20.75
32.04%
Biontech Se
Biontech Se
Buy
$27.1B
487.66%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
198.57%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.9B
136.25%
32.84
-4.74%

Insights on Cellectar Biosciences Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.7% return, outperforming this stock by 87.1%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 58.4% return, outperforming this stock by 137.3%

Institutional Holdings

  • Nantahala Capital Management, LLC

    10.23%
  • AIGH Capital Management, LLC

    8.47%
  • Rosalind Advisors, Inc.

    7.55%
  • Vanguard Group Inc

    4.36%
  • ADAR1 Capital Management LLC

    1.90%
  • Geode Capital Management, LLC

    0.95%

Company Information

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p

Organization
Cellectar Biosciences Inc
Employees
20
CEO
Mr. James V. Caruso
Industry
Health Technology

FAQs